Table 1: Summary of clinical features in radiation-associated angiosarcoma (RAA) patients.

Case no.SexPrimary DxAge 1° DxRxRT dose (Gy)Interval to RAA (mos)RAA TxStatusInterval to death or last f/u (mos)

1FL breast CA50L/RT/Raloxifene6037Gem, taxotere/MDOD6.1
2FL breast CA57L/RT64.689Adria, ifos/M (bil) A-NED41.3
3FL breast CA70L/RT6063M/taxolA-NED33.2
4FR breast CA50L/RT6157Adria, ifos/MA-NED102.0
5FR breast CA74L/RT/Tm5284Vinb, actin-D/MA-NED52.2
6FR breast CA53L/C/RT/Tm64.693M (bil)/Adria, ifosA-NED23.5
7FL breast CA51L/C/RT54141M/Adria, ifos/RT/Adria, ifosA2.8
8FSCC, R Cheek68WLE/RT70.278WLE/RT (palliative)DOD11.0
9MSeminoma26WLE/RTCo × 6 wks419Ifos/WLE/RT (63 Gy)DOD39.2
10MProstate CA72WLE/RT72120WLED10.2
11FHodgkin’s lymphoma16C/total nodal RTNA387Adria, ifos/amputationDOD15.1

CA: carcinoma, SCC: squamous cell carcinoma, L: lumpectomy, RT: radiation therapy, C: chemotherapy, Gem: gemcitabine, Adria: adriamycin, Ifos: ifosfamide, Tm: tamoxifen, M: mastectomy, WLE: wide local excision, D: dead, DOD: dead of disease, A: alive, A-NED: alive-no evidence of disease.